1910 Genetics
Bridget Cole is a highly experienced scientific leader in the biopharmaceutical and biotechnology sectors, currently serving as Chief Scientific Officer at 1910 Genetics since May 2023. Previously, Bridget held senior roles at Nocion Therapeutics, Inc., where responsibilities included Senior Vice President and Head of Chemistry, focusing on developing novel treatments for silencing neurons. Throughout a distinguished career, Bridget contributed as Vice President at Axial Biotherapeutics, Flatley Discovery Lab, and Surface Logix, directing research that led to advancements in drug discovery and development, particularly in areas like Cystic Fibrosis and metabolic disorders. Bridget's early career included significant roles at Pfizer Laboratories, culminating in leadership positions involving the discovery of key compounds for treating type-2 diabetes and obesity. Educational credentials include a Ph.D. in Chemistry from Brandeis University, complemented by postdoctoral research at Boston College and a BA in Chemistry from Boston University.
1910 Genetics
3 followers
1910 Genetics is a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Their mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.